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Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu) TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients We previously reported that TG101209, a JAK2-selective small molecule inhibitor, inhibits ex vivo hematopoietic colony growth in the context of myeloproliferative disorder (MPD)-relevant JAK2V617F and MPLW515L/K mutations. 1, 2 More recently, phase I testing in the clinic has started with a related compound, TG101348, for the treatment of myelofibrosis patientsFcurrently, those with intermediate-or high-risk disease, relapsed/ refractory disease or symptomatic splenomegaly are eligible to participate, irrespective of JAK2V617F mutation status. Two recent reports have shown TG101348 to be effective in treating a murine model of JAK2V617F-induced MPD and in inhibiting the engraftment of polycythemia vera (PV) progenitor cells in a mouse xenotransplant model, respectively. 3, 4 Using leukemic cell lines and primary cells from MPD patients, we sought to address the following clinically relevant questions pertaining to TG101348 in the context of the aforementioned clinical trial: (i) is there a 'therapeutic window' vis-à-vis inhibition of normal hematopoietic progenitor cell growth? (ii) is the growth of mutation-harboring colonies selectively suppressedFis this effect equipotent in the presence and absence of exogenous erythropoietin (Epo) (that is, does Epo counteract the inhibitory effect of TG101348)? (iii) does the presence of JAK2 exon 12 mutations also confer sensitivity to inhibition with TG101348? and (iv) are MPD patients from whom mutations have not yet been identified as sensitive to JAK2 inhibition as patients with known mutations?
Cell proliferation was assessed using the XTT assay. 1 The inhibitory effect of TG101348 on ex vivo hematopoietic colony growth was studied in 15 MPD patients (12 PV patients with JAK2V617F; one PV patient with an JAK2 exon 12 mutation (N542-E543del); one primary myelofibrosis (PMF) patient with MPLW515K; one PMF patient without identifiable mutation), and two healthy controls (Table 1) . Peripheral blood samples Abbreviations: IFN-g, interferon-g; TNF-a, tumor necrosis factor-a; IL-2, interleukin-2. IFN-g, TNF-a and IL-2 cytokine production by patient and UCB graft unit mixed lymphocyte reactions after 72 h. Reported numbers are the increase in cytokine production between UCB graft units and UCB graft units with patient cells.
Letters to the Editor were collected after informed consent and the mononuclear cell fraction was plated at a concentration of 3 Â 10 5 per plate with and without erythropoietin, as described previously.
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TG101348 was added at the following concentrations: 0, 300, 600 and 1200 nM. Colonies were scored and isolated for individual genotyping on or around day 14. Genotyping for JAK2V617F and MPLW515K mutations was performed by PCR sequencing.
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TG101348 inhibited the cytokine-independent growth of human erythroleukemia and Ba/F3-JAK2V617F cells (IC 50 ¼ 300 and 580 nM, respectively) as well as Ba/F3-MPLW515L cells (IC 50 ¼ 620 nM), but was considerably less effective at inhibiting growth of BCR-ABL harboring K562 cells (IC 50 ¼ 5000 nM) (data not shown). JAK2:JAK3 selectivity of TG101348 was assessed using leukemic cell lines harboring either JAK2 or JAK3 activated allelesFCHRF cells (JAK2T875N) were 10 Â more potently inhibited than CMK cells (JAK3A572V) in this experiment (IC 50 ¼ 60 and 600 nM, respectively). TG101348 significantly attenuated the size of erythroid colonies (erythroid burst-forming unit) obtained from PV progenitor cells. The erythroid burst-forming unit growth was suppressed more potently (twofold or better) relative to normal progenitor cells, and the inhibitory effect was uniformly more pronounced in the absence of Epo (Table 1 ). The latter is consistent with a greater incidence of JAK2V617F in Epo-independent 'endogenous' erythroid colonies relative to the Epo-supported colonies. Furthermore, genotyping of individual colonies obtained in the presence of TG101348 showed relatively selective suppression JAK2 mutation-harboring colonies in all six PV patients studied (PV1-PV5 with exon 14 and PV13 with exon 12 mutations), irrespective of Epo presence. The inhibitory effect on colony growth was similar with MPLW515K (PMF1) or in the absence of JAK2 or MPLW515 mutations (PMF2) ( Table 1) .
We conclude from the aforementioned experiments that: (i) there is a therapeutic window for this inhibitor in the treatment of MPD patients; (ii) the mutation-harboring clone is selectively suppressed, an observation that correlates with the reduction in JAK2V617F allele burden seen in mouse experiments; (iii) addition of exogenous Epo may attenuate but does not completely counteract the TG101348 inhibitory effectFin the absence of inhibitor, Epo supports the relative outgrowth of mutation-negative clones; and (iv) other MPD-relevant mutations are equipotently inhibited as JAK2V617F, thus indicating that the abnormal MPD clone in such cases may be as dependent on dysregulated JAK-STAT signaling as those with known JAK2-or MPL-mutations. In up to 30% of acute myeloid leukemia (AML), chromosomal translocations disrupt one of the core binding factor (CBF) genes most frequently by the t(8;21)(q22;q22). Although patients with CBF leukemia generally have a higher complete remission rate and disease-free survival as compared to those with a normal karyotype or other chromosomal aberrations, additional distinct mutations in genes involved in signal-transduction pathways, particularly in receptor tyrosine kinases (RTKs), herald a higher relapse rate (see below). The 2-hit hypothesis proposes that most acute leukemias are the consequence of a collaboration of several types of mutations.
Disclosures
1 Class I mutations often affect genes of RTKs, which confer a proliferative and survival advantage to hematopoietic progenitors. Class II mutations are usually chromosomal translocations involving hematopoietic transcription factors, with consecutive impairment of differentiation and apoptosis of cells. Mouse models with high transgene expression of the fusion protein AML1/ETO do not develop leukemia spontaneously. 2 In contrast, specific additional mutational events, for example, FLT3 length mutations, can promote development of leukemia in an AML1/ETO mouse model. 3 There is evidence in cells haploinsufficient for AML1 suggesting a similar cooperative role for the RTK c-kit. 
